Sign In
Media & Investors
Skip Navigation LinksSanten > United Kingdom > Media & Investors > News > Santen announces appointment of Shigeo Taniuchi as Head of Santen Europe
Contact
Santen Pharmaceutical welcomes your enquiries and opinions

Santen announces appointment of Shigeo Taniuchi as Head of Santen Europe

 
4/2/2015

Munich, Germany – April 2, 2015 (US-EST) – Santen GmbH (Munich, Germany) (Santen) announced the appointment of Shigeo Taniuchi to the position of Head of Santen Europe. In this role, Mr. Taniuchi will manage the Company's business strategies and operations in Europe, effective April 1st, 2015. Mr. Taniuchi joined Santen in 1996 in Japan.

 

Mr. Taniuchi brings 15 years of top-level management experience and global business leadership in Santen. From September 2014, Shigeo served as Senior Vice President, Commercialization for Santen Europe. Previously he held management positions in Santen as General Manager, Corporate Planning and Corporate Development Division for Santen in Osaka, Japan. He was also responsible for commercial operations in China developing strategic initiatives to transform business model in the country. He was also been in charge of strategy building and implementation for Asia business of Santen.

 

Shigeo Taniuchi, Head of Santen Europe, comments:

"I am very pleased to lead the development of Santen's business in Europe in order for the company to become one of the major companies of reference in ophthalmology in Europe. I am looking forward to working closely with customers and Santen's European team, in order to reinforce our presence and become a key player in the European ophthalmic sector. Santen is on the right track for continued growth and expansion with innovative products and services to improve patient vision and quality of life."

 

In the 1990s, Santen started commercial activities in Germany, Nordic and Central Europe countries. Since then the company has expanded its presence and today Santen has commercial activities across Europe with a focus on Glaucoma and Dry Eye. In March 2015, Santen obtained a European Marketing Authorization from the European Commission for Ikervis®, the first drug for the treatment of severe keratitis in adult patients with dry eye disease in Europe.

About Santen

As a specialty company dedicated to the ophthalmic and anti-rheumatic fields, Santen carries out the research, development, sales, and marketing of pharmaceuticals. The company has its bases in about 20 countries and delivers products in more than 70 countries. In Japan, Santen holds the No. 1 share in the prescription ophthalmic pharmaceutical market. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs.

Santen Forward-looking Statements

Information provided in this press release contains so-called "Forward-looking Statements". The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial condition are subject to the effects of change in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

 

This press release is also prepared in other languages. However this English document is the original document, and documents prepared in other languages are for your reference only. In case of any discrepancy between the English and translated versions, the English version will prevail. Please refer to http://www.santen.eu for the original English document.

Contacts

​Media Relations

Nicolas Merigeau

Emmanuel Huynh

NewCap.

nmerigeau@newcap.fr

Tel: +33-1-4471-9498

​Santen

Geneviève Garrigos

Corporate Communication Director - Santen Europe

Tel: +33-6-6554-6019